{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:06:09Z","timestamp":1789103169061,"version":"build-2803163510"},"reference-count":115,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Bialystok"},{"id":[{"id":"https:\/\/ror.org\/00y4ya841","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Oral nanocarrier development for inflammatory bowel disease (IBD) is complicated by inflammation-dependent changes in mucus, epithelial integrity, and immune-cell interactions. This critical narrative review examines comparative evidence from in vitro systems, animal models, and human intestinal tissue, alongside clinical studies, to assess how barrier state modifies formulation performance. Across the reviewed studies, particle size alone does not consistently predict lesion accumulation, while surface chemistry, coating, geometry, and stability in gastrointestinal fluids influence mucus interaction, cellular access, and payload release. Tissue-associated fluorescence, increased permeability, and cellular uptake do not independently establish intact-carrier transport or productive delivery. Clinical trials of selected oral nano-enabled formulations report improvements in some disease outcomes but do not establish inflammation-selective delivery as the underlying mechanism. We propose an evidence-informed benchmarking framework linking characterization in biological media to mucus transport or retention, epithelial\u2013immune responses, spatial localization, target engagement, and safety. Matched healthy and inflamed comparators are central to testing selectivity, and preclinical findings must be distinguished from clinical validation. Artificial intelligence may support barrier-state-aware formulation optimization but requires standardized datasets and prospective experimental validation. Given the heterogeneous evidence base and limited direct human delivery studies, prospective validation should prioritize local payload delivery and therapeutic benefit without exacerbating intestinal barrier injury.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091132","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:05:43Z","timestamp":1788941143000},"page":"1132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Inflamed Intestinal Barrier as a Formulation Variable in Oral Nanocarrier Design: Evidence-Informed Principles for Mucus Interaction, Epithelial Access, and Translational Testing"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8133-8335","authenticated-orcid":false,"given":"Zofia","family":"\u015aledzikowska","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Medical University of Bialystok, Micha\u0142a Wo\u0142odyjowskiego 2, 15-272 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"\u017byli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical University of Bialystok, Micha\u0142a Wo\u0142odyjowskiego 2, 15-272 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Makaruk","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical University of Bialystok, Micha\u0142a Wo\u0142odyjowskiego 2, 15-272 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7365-1608","authenticated-orcid":false,"given":"Dominika","family":"Kubicka","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical University of Bialystok, Micha\u0142a Wo\u0142odyjowskiego 2, 15-272 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip Adam","family":"B\u0142otniak","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical University of Bialystok, Micha\u0142a Wo\u0142odyjowskiego 2, 15-272 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7021-5133","authenticated-orcid":false,"given":"Napoleon","family":"Waszkiewicz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical University of Bialystok, Micha\u0142a Wo\u0142odyjowskiego 2, 15-272 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Garbati, P., Picco, C., Magrassi, R., Signorello, P., Cacopardo, L., Dalla Serra, M., Faticato, M.G., De Luca, M., Balestra, F., and Scavo, M.P. (2024). Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16030431"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.2147\/DDDT.S461977","article-title":"Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment","volume":"18","author":"Gao","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ribeiro, A., and Nunes, R. (2026). Selective Nanoparticulate Systems for Drug Delivery in Inflammatory Bowel Disease. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18010055"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1039\/D4TB02868F","article-title":"Precision therapeutics for inflammatory bowel disease: Advancing ROS-responsive nanoparticles for targeted and multifunctional drug delivery","volume":"13","author":"Wan","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"ref_5","first-page":"100377","article-title":"Biomimetic nanocarriers for the therapy and management of intestinal inflammations","volume":"10","author":"Bera","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tan, A.X.X., Ong, B.Y.C., Dinesh, T., and Srinivasan, D.K. (2025). Nanomedicine Strategies in the Management of Inflammatory Bowel Disease and Colorectal Cancer. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202506.0784.v1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2012.01.028","article-title":"Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa","volume":"161","author":"Collnot","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.2147\/IJN.S210315","article-title":"Nanoparticle-mediated drug delivery systems for the treatment of IBD: Current perspectives","volume":"14","author":"Yang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/btm2.10122","article-title":"Nanocrystals: A perspective on translational research and clinical studies","volume":"4","author":"Jarvis","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1007\/s13346-024-01559-0","article-title":"Nanocrystals and nanosuspensions: An exploration from classic formulations to advanced drug delivery systems","volume":"14","author":"Rossier","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wang, C., Wang, M., Chen, P., Wang, J., and Le, Y. (2022). Dasatinib Nanoemulsion and Nanocrystal for Enhanced Oral Drug Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010197"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jconrel.2016.06.016","article-title":"Nanoparticles for oral delivery: Design, evaluation and state-of-the-art","volume":"240","author":"Date","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.biomaterials.2016.06.018","article-title":"Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer","volume":"101","author":"Zhang","year":"2016","journal-title":"Biomaterials"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.7150\/thno.73650","article-title":"Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis","volume":"12","author":"Gao","year":"2022","journal-title":"Theranostics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2468-1253(24)00390-X","article-title":"The intestinal barrier: A pivotal role in health, inflammation, and cancer","volume":"10","author":"Neurath","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12951-022-01539-x","article-title":"Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems","volume":"20","author":"Subramanian","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103717","DOI":"10.1016\/j.autrev.2024.103717","article-title":"Intestinal mucus barrier: A potential therapeutic target for IBD","volume":"24","author":"Qiao","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s12951-024-02930-6","article-title":"Intestinal nanoparticle delivery and cellular response: A review of the bidirectional nanoparticle-cell interplay in mucosa based on physiochemical properties","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0126-x","article-title":"Mechanisms regulating intestinal barrier integrity and its pathological implications","volume":"50","author":"Chelakkot","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00784-017-2172-5","article-title":"The effect of saliva on the fate of nanoparticles","volume":"22","author":"Teubl","year":"2018","journal-title":"Clin. Oral Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.2147\/IJN.S221608","article-title":"Nanoparticles and human saliva: A step towards drug delivery systems for dental and craniofacial biomaterials","volume":"14","author":"Pokrowiecki","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/17425247.2019.1610384","article-title":"Oral delivery of nanoparticles\u2014let\u2019s not forget about the protein corona","volume":"16","author":"Berardi","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/med.21767","article-title":"Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles","volume":"41","author":"Zhang","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104738","DOI":"10.1016\/j.tiv.2019.104738","article-title":"Ongoing inflammation enhances the toxicity of engineered nanomaterials: Application of an in vitro co-culture model of the healthy and inflamed intestine","volume":"63","author":"Urban","year":"2020","journal-title":"Toxicol. Vitr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1023\/A:1011032328064","article-title":"Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa","volume":"18","author":"Lamprecht","year":"2001","journal-title":"Pharm. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2012.10.019","article-title":"Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: A first in vivo study in human patients","volume":"165","author":"Schmidt","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"20175","DOI":"10.1038\/s41598-023-47445-6","article-title":"Surface functionalization affects the retention and bio-distribution of orally administered mesoporous silica nanoparticles in a colitis mouse model","volume":"13","author":"Schmid","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2013.07.031","article-title":"Surfactant-dependence of nanoparticle treatment in murine experimental colitis","volume":"172","author":"Wachsmann","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.carbpol.2016.01.026","article-title":"Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa","volume":"144","author":"Vafaei","year":"2016","journal-title":"Carbohydr. Polym."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e2306482","DOI":"10.1002\/smll.202306482","article-title":"Selective Uptake Into Inflamed Human Intestinal Tissue and Immune Cell Targeting by Wormlike Polymer Micelles","volume":"20","author":"Gardey","year":"2024","journal-title":"Small"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/17435889.2025.2465247","article-title":"Nanoencapsulation enhanced the performance of \u03b2-carotene for ameliorating inflammation in patient-derived organoids","volume":"20","author":"Ngew","year":"2025","journal-title":"Nanomedicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/s00210-025-04484-2","article-title":"Evaluation of oral nano-curcumin formulation effectiveness in patients with mild to moderate ulcerative colitis: A randomized, placebo-controlled, double-blind clinical trial","volume":"399","author":"Daryani","year":"2026","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1002\/jcb.27273","article-title":"The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients\u2019 self-reported well-being: A randomized double-blind controlled trial","volume":"119","author":"Masoodi","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1097\/MCG.0000000000001233","article-title":"Oral Nano Vitamin D Supplementation Reduces Disease Activity in Ulcerative Colitis: A Double-Blind Randomized Parallel Group Placebo-controlled Trial","volume":"53","author":"Ahamed","year":"2019","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1208\/s12249-022-02327-4","article-title":"Mucus-Penetrating Alginate-Chitosan Nanoparticles Loaded with Berberine Hydrochloride for Oral Delivery to the Inflammation Site of Ulcerative Colitis","volume":"23","author":"Sun","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jconrel.2022.03.037","article-title":"Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1","volume":"345","author":"Hartwig","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_38","first-page":"53","article-title":"A 3D co-culture of three human cell lines to model the inflamed intestinal mucosa for safety testing of nanomaterials","volume":"10","author":"Susewind","year":"2016","journal-title":"Nanotoxicology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2014.03.039","article-title":"Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases","volume":"183","author":"Ali","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejpb.2015.01.023","article-title":"Nanoparticle diffusion within intestinal mucus: Three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, PEGylated and viral particles","volume":"97","author":"Abdulkarim","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/1061186X.2015.1086359","article-title":"Size selectivity of intestinal mucus to diffusing particulates is dependent on surface chemistry and exposure to lipids","volume":"23","author":"Yildiz","year":"2015","journal-title":"J. Drug Target."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.colsurfb.2015.07.038","article-title":"The influence of small intestinal mucus structure on particle transport ex vivo","volume":"135","author":"Bajka","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1007\/s12274-017-1918-3","article-title":"Surface charge tunable nanoparticles for TNF-\u03b1 siRNA oral delivery for treating ulcerative colitis","volume":"11","author":"Iqbal","year":"2018","journal-title":"Nano Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"PEGylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1021\/acs.nanolett.6b03515","article-title":"Rotation-Facilitated Rapid Transport of Nanorods in Mucosal Tissues","volume":"16","author":"Yu","year":"2016","journal-title":"Nano Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jmps.2017.12.014","article-title":"Diffusion of rod-like nanoparticles in non-adhesive and adhesive porous polymeric gels","volume":"112","author":"Wang","year":"2018","journal-title":"J. Mech. Phys. Solids"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., and Mozafari, M.R. (2018). Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10020057"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2016.06.017","article-title":"DLS and zeta potential\u2014What they are and what they are not?","volume":"235","author":"Bhattacharjee","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1039\/D3MH00717K","article-title":"Dynamic light scattering and transmission electron microscopy in drug delivery: A roadmap for correct characterization of nanoparticles and interpretation of results","volume":"10","author":"Filippov","year":"2023","journal-title":"Mater. Horiz."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"20417314241265892","DOI":"10.1177\/20417314241265892","article-title":"Oral delivery of pH-sensitive nanoparticles loaded celastrol targeting the inflammatory colons to treat ulcerative colitis","volume":"15","author":"Zhao","year":"2024","journal-title":"J. Tissue Eng."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nmat2859","article-title":"Orally delivered thioketal nanoparticles loaded with TNF-\u03b1-siRNA target inflammation and inhibit gene expression in the intestines","volume":"9","author":"Wilson","year":"2010","journal-title":"Nat. Mater."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"100246","DOI":"10.1016\/j.mtbio.2022.100246","article-title":"ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment","volume":"14","author":"Tan","year":"2022","journal-title":"Mater. Today Bio"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12951-023-02045-4","article-title":"Oral hydrogel nanoemulsion co-delivery system treats inflammatory bowel disease via anti-inflammatory and promoting intestinal mucosa repair","volume":"21","author":"Lei","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1186\/s12967-024-05662-1","article-title":"Oral colon-targeted pH-responsive polymeric nanoparticles loading naringin for enhanced ulcerative colitis therapy","volume":"22","author":"Fan","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1007\/s12274-024-6435-6","article-title":"ROS-responsive nanoparticles targeting inflamed colon for synergistic therapy of inflammatory bowel disease via barrier repair and anti-inflammation","volume":"17","author":"Wang","year":"2024","journal-title":"Nano Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000519363","article-title":"Macrophage-biomimetic nanoparticles ameliorate ulcerative colitis through reducing inflammatory factors expression","volume":"14","author":"Li","year":"2022","journal-title":"J. Innate Immun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"146796","DOI":"10.1016\/j.cej.2023.146796","article-title":"Macrophage-biomimetic liposomes delivery of carbon dots nanozymes ameliorate ulcerative colitis by modulating inflammation pathways and remodeling the redox microenvironment","volume":"477","author":"Ma","year":"2023","journal-title":"Chem. Eng. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ibd\/izaf293","article-title":"Clinical Significance of Mucin Signatures in Inflammatory Bowel Diseases: A Systematic Review of Their Expression Patterns, Polymorphisms, and Post-translational Modifications","volume":"32","author":"Arras","year":"2026","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/gutjnl-2012-303207","article-title":"Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis","volume":"63","author":"Johansson","year":"2014","journal-title":"Gut"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Pearce, S.C., Al-Jawadi, A., Kishida, K., Yu, S., Hu, M., Fritzky, L.F., Edelblum, K.L., Gao, N., and Ferraris, R.P. (2018). Marked differences in tight junction composition and macromolecular permeability among different intestinal cell types. BMC Biol., 16.","DOI":"10.1186\/s12915-018-0481-z"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mi.2013.30","article-title":"Microfold (M) cells: Important immunosurveillance posts in the intestinal epithelium","volume":"6","author":"Mabbott","year":"2013","journal-title":"Mucosal Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"120167","DOI":"10.1016\/j.ijpharm.2020.120167","article-title":"An ex vivo investigation of the intestinal uptake and translocation of nanoparticles targeted to Peyer\u2019s patches microfold cells","volume":"594","author":"Jia","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.gastro.2022.10.014","article-title":"Intestinal Barrier Healing Is Superior to Endoscopic and Histologic Remission for Predicting Major Adverse Outcomes in Inflammatory Bowel Disease: The Prospective ERIca Trial","volume":"164","author":"Rath","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"McCright, J., Ramirez, A., Amosu, M., Sinha, A., Bogseth, A., and Maisel, K. (2021). Targeting the gut mucosal immune system using nanomaterials. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111755"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3892\/br.2022.1536","article-title":"Role of myeloperoxidase in inflammation and atherosclerosis","volume":"16","author":"Frangie","year":"2022","journal-title":"Biomed. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s44164-023-00047-y","article-title":"A human Caco-2-based co-culture model of the inflamed intestinal mucosa for particle toxicity studies","volume":"2","author":"Paul","year":"2023","journal-title":"In Vitro Models"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.bbrc.2020.11.047","article-title":"Oral intake of silica nanoparticles exacerbates intestinal inflammation","volume":"534","author":"Ogawa","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/MIB.0b013e3182813297","article-title":"Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts","volume":"19","author":"Johnson","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e179472","DOI":"10.1172\/JCI179472","article-title":"TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn\u2019s disease","volume":"134","author":"Zhang","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","article-title":"Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases","volume":"569","author":"Arze","year":"2019","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"G341","DOI":"10.1152\/ajpgi.00046.2013","article-title":"Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer\u2019s patches","volume":"305","author":"Ermund","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12989-024-00563-z","article-title":"The in vitro gastrointestinal digestion-associated protein corona of polystyrene nano- and microplastics increases their uptake by human THP-1-derived macrophages","volume":"21","author":"Brouwer","year":"2024","journal-title":"Part Fibre Toxicol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1038\/s41467-026-70453-9","article-title":"Surface hydrophobicity and rigidity determines protein corona on orally delivered nanoparticles treating colitis","volume":"17","author":"Wu","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11443","DOI":"10.1021\/acsami.7b19153","article-title":"Intestinal Mucin Induces More Endocytosis but Less Transcytosis of Nanoparticles across Enterocytes by Triggering Nanoclustering and Strengthening the Retrograde Pathway","volume":"10","author":"Yang","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e2402249","DOI":"10.1002\/smtd.202402249","article-title":"Tracking In Vivo Lipolysis of Lipid Nanocarriers Using NIR-II Polarity-Sensitive Fluorescent Probes","volume":"9","author":"Zhan","year":"2025","journal-title":"Small Methods"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chom.2018.10.001","article-title":"Plant-Derived Exosomal MicroRNAs Shape the Gut Microbiota","volume":"24","author":"Teng","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Pad\u00edn-Gonz\u00e1lez, E., Lancaster, P., Bottini, M., Gasco, P., Tran, L., Fadeel, B., Wilkins, T., and Monopoli, M.P. (2022). Understanding the role and impact of poly(ethylene glycol) on nanoparticle formulation: Implications for COVID-19 vaccines. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.882363"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e1601556","DOI":"10.1126\/sciadv.1601556","article-title":"Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation","volume":"3","author":"Schneider","year":"2017","journal-title":"Sci. Adv."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"108967","DOI":"10.1016\/j.cclet.2023.108967","article-title":"Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy","volume":"35","author":"Zhou","year":"2024","journal-title":"Chin. Chem. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1186\/s12951-025-03829-6","article-title":"Flexibility-powered Pickering emulsion enhances mucus permeability to alleviate ulcerative colitis","volume":"23","author":"Lv","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/10837450.2021.1873370","article-title":"Mucoadhesive chitosan and thiolated chitosan nanoparticles containing alpha mangostin for possible colon-targeted delivery","volume":"26","author":"Samprasit","year":"2021","journal-title":"Pharm. Dev. Technol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"20809","DOI":"10.1039\/C8RA01898G","article-title":"Biodistribution and targeting potential assessment of mucoadhesive chitosan nanoparticles designed for ulcerative colitis via scintigraphy","volume":"8","author":"Raj","year":"2018","journal-title":"RSC Adv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.progpolymsci.2014.07.010","article-title":"Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review","volume":"39","author":"Sosnik","year":"2014","journal-title":"Prog. Polym. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Xie, D., Zhou, X., Xiao, B., Duan, L., and Zhu, Z. (2022). Mucus-Penetrating Silk Fibroin-Based Nanotherapeutics for Efficient Treatment of Ulcerative Colitis. Biomolecules, 12.","DOI":"10.3390\/biom12091263"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"121707","DOI":"10.1016\/j.biomaterials.2022.121707","article-title":"Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: A novel therapeutic solution to treat ulcerative colitis","volume":"288","author":"Sung","year":"2022","journal-title":"Biomaterials"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Mow, R.J., Kuczma, M.P., Shi, X., Mani, S., Merlin, D., and Yang, C. (2024). Harnessing a safe novel lipid nanoparticle: Targeted oral delivery to colonic epithelial and macrophage cells in a colitis mouse model. Nanomaterials, 14.","DOI":"10.3390\/nano14221800"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Li, D., Du, L., Yi, G., Liang, T., Midgley, A.C., Shu, G., He, Y., Dong, Y., Li, G., and Yao, X. (2026). Extremophyte-derived exosome-like nanovesicles remodel intestinal barrier dysfunction by multi-dimensional intervention: Physical barrier repair with immune homeostasis and microbiome regulation. J. Nanobiotechnol., Epub ahead of printing.","DOI":"10.1186\/s12951-026-04800-9"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.actbio.2020.09.017","article-title":"Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis","volume":"116","author":"Naeem","year":"2020","journal-title":"Acta Biomater."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Roussel, S., Grenier, P., Ch\u00e9nard, V., and Bertrand, N. (2023). Dual-Labelled Nanoparticles Inform on the Stability of Fluorescent Labels In Vivo. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030769"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2016.06.027","article-title":"Integrity of lipid nanocarriers in bloodstream and tumor quantified by near-infrared ratiometric FRET imaging in living mice","volume":"236","author":"Bouchaala","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1039\/D4TB02653E","article-title":"Capturing the dynamic integrity of carbocyanine fluorophore-based lipid nanoparticles using the FRET technique","volume":"13","author":"Long","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Huang, B., An, H., Chen, L., Qiu, Y., Su, Y., Shen, S., Wu, H., Li, M., Lu, L., and Wang, R. (2025). Diabetes as an independent risk factor for severe inflammatory bowel disease: Evidence from an inflammation\u2013metabolism\u2013liver coupling framework. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1707507"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","article-title":"Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue","volume":"11","author":"Hua","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijpharm.2012.07.017","article-title":"Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies","volume":"440","author":"Coco","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"121364","DOI":"10.1016\/j.biomaterials.2022.121364","article-title":"Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease","volume":"281","author":"Kotla","year":"2022","journal-title":"Biomaterials"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Ritarossi, C., Prota, V., De Battistis, F., Battistelli, C.L., De Angelis, I., Andreoli, C., and Vincentini, O. (2025). Nanoparticle uptake and crossing by human in vitro models of intestinal barriers: A scoping review. Nanomaterials, 15.","DOI":"10.3390\/nano15151195"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Lechuga, S., Braga-Neto, M.B., Naydenov, N.G., Rieder, F., and Ivanov, A.I. (2023). Understanding disruption of the gut barrier during inflammation: Should we abandon traditional epithelial cell lines and switch to intestinal organoids?. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1108289"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"G403","DOI":"10.1152\/ajpgi.00087.2025","article-title":"Emerging advances in intestinal models for in vitro preclinical research","volume":"329","author":"Adesina","year":"2025","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M.T., Baker, M., Browne, W.J., Clark, A., Cuthill, I.C., and Dirnagl, U. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3000410"},{"key":"ref_103","unstructured":"Center for Open Science (2026, September 01). Registered Reports. Available online: https:\/\/www.cos.io\/initiatives\/registered-reports."},{"key":"ref_104","unstructured":"PLOS ONE (2026, September 01). Criteria for Publication. Available online: https:\/\/journals.plos.org\/plosone\/s\/criteria-for-publication."},{"key":"ref_105","unstructured":"U.S. Food and Drug Administration (2026, August 31). Ulcerative Colitis: Developing Drugs for Treatment. Draft Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/158016\/download."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/1078-0432.CCR-16-3193","article-title":"64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer","volume":"23","author":"Lee","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_107","unstructured":"U.S. Food and Drug Administration (2026, August 31). Drug Products, Including Biological Products, that Contain Nanomaterials. Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/157812\/download."},{"key":"ref_108","unstructured":"International Council for Harmonisation (2026, August 31). Q8(R2): Pharmaceutical Development, Available online: https:\/\/www.fda.gov\/media\/71535\/download."},{"key":"ref_109","unstructured":"International Council for Harmonisation (2026, August 31). Q1A(R2): Stability Testing of New Drug Substances and Products, Available online: https:\/\/www.fda.gov\/media\/71707\/download."},{"key":"ref_110","unstructured":"World Health Organization (2026, August 31). Target Product Profiles, Preferred Product Characteristics and Target Regimen Profiles. Available online: https:\/\/www.who.int\/our-work\/science-division\/research-for-health\/optimizing-research-processes\/product-profiles."},{"key":"ref_111","unstructured":"National Cancer Institute (2026, August 31). Cancer Nanomedicine Assay Cascade Characterization Service, Available online: https:\/\/dctd.cancer.gov\/drug-discovery-development\/assays\/nano\/assay-cascade-characterization-service."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"026103","DOI":"10.1063\/5.0091025","article-title":"Machine learning-informed predictions of nanoparticle mobility and fate in the mucus barrier","volume":"6","author":"Kaler","year":"2022","journal-title":"APL Bioeng."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Seo, J.H., and Mittal, R. (2022). Computational Modeling of Drug Dissolution in the Human Stomach. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.755997"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1038\/s41467-026-72482-w","article-title":"Spatial transcriptomics atlas of inflammatory bowel disease to guide implementation in research consortiums and clinical trials","volume":"17","author":"Li","year":"2026","journal-title":"Nat. Commun."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:18:10Z","timestamp":1789100290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":115,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091132"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091132","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}